Karolina Machowska-Sempruch

Dr. Karolina Machowska-Sempruch

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BBBartłomiej Baumert
Bartłomiej Baumert
ASAnna Sobuś
Anna Sobuś
MGMONIKA GOŁĄB-JANOWSKA
MONIKA GOŁĄB-JANOWSKA
ZUZofia Ulańczyk
Zofia Ulańczyk
EPEdyta Paczkowska
Edyta Paczkowska
BMBogusław Machaliński
Bogusław Machaliński
Amyotrophic lateral sclerosis (ALS) remains a fatal disease with limited therapeutic options. Signaling via neurotrophins (NTs), neuroinflammation, and certain micro-RNAs are believed to play essential role in ALS pathogenesis. Lineage-negative stem/progenitor cells (Lin−) were obtained from bone marrow of 18 ALS patients and administered intrathecally. Clinical assessment was performed using ALS Functional Rating Scale (FRSr) and Norris scale. Protein concentrations were measured in plasma and cerebrospinal fluid (CSF) by multiplex fluorescent bead-based immunoassay. Gene expression in nucleated blood cells was assessed using gene microarray technique. Finally, miRNA expression was analyzed using qPCR in CSF and plasma samples. We observed a significant decrease of C-reactive protein (CRP) concentration in plasma on the seventh day from the application of cells. Gene array results revealed decreased expression of gene sets responsible for neutrophil activation. Further analysis revealed moderate negative correlation between CRP level in CSF and clinical outcome. Brain-derived neurotrophic factor (BDNF) concentrations in both plasma and CSF significantly correlated with the favorable clinical outcome. On a micro-RNA level, we observed significant increase of miR-16-5p expression one week after transplantation in both body fluids and significant increase of miR-206 expression in plasma. Administration of Lin− cells may decrease inflammatory response and prevent neurodegeneration. However, these issues require further investigations.

1 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KMKrystian Mross
Krystian Mross
MJMarta Jankowska
Marta Jankowska
AMAgnieszka Meller
Agnieszka Meller
KMKarolina Machowska-Sempruch
Karolina Machowska-Sempruch
PNPrzemysław Nowacki
Przemysław Nowacki
WPWioletta Pawlukowska
Wioletta Pawlukowska
Sensory integration disorder (SID) is also called, interchangeably, sensory processing disorder (SPD). Multiple sclerosis (MS) is an autoimmune, chronic, neurological disease of the central nervous system. Sensorimotor function disorders are present in both multiple sclerosis and SID. The study aimed to assess the SID among patients with MS and included 141 patients with relapse-remitting MS and 72 participants in the control group. To assess SID in both groups, a questionnaire prepared by Daniel Travis was used. Additionally, participants answered questions regarding their age, gender, handedness and in the study group about the duration of the disease, relapses in the past year and the advancement of the disease using EDSS. The occurrence of sensory seeking was significantly more frequent in the MS patients with relapses in the past year. Patients with MS had more often general disorders of sensory integration in the past. However, healthy subjects significantly more often showed the severity of social and emotional disorders in the past. Currently, the group of MS patients has a greater intensity of sensor-based motor abilities. The study revealed more severe SID in MS patients than in the control group. Still, more research is needed in this field.

1 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
BBBartłomiej Baumert
Bartłomiej Baumert
ASAnna Sobuś
Anna Sobuś
MGMONIKA GOŁĄB-JANOWSKA
MONIKA GOŁĄB-JANOWSKA
EPEdyta Paczkowska
Edyta Paczkowska
KŁKarolina Łuczkowska
Karolina Łuczkowska
BMBogusław Machaliński
Bogusław Machaliński
Therapeutic interventions in amyotrophic lateral sclerosis (ALS) are still far from satisfying. Immune modulating procedures raise hopes for slowing the disease progression. Stem cell therapies are believed to possess the ability to regulate innate and adaptive immune response and inflammation processes. Hence, three intrathecal administrations of autologous bone marrow-derived lineage-negative (Lin–) cells were performed every six weeks in 40 sporadic ALS patients. The concentrations of inflammatory-related proteins and expression profiles of selected miRNA in the cerebrospinal fluid (CSF) and plasma at different timepoints post-transplantation were quantified by multiplex Luminex and qRT-PCR. The global gene expression in nucleated blood cells was assessed using the gene microarray technique. According to the ALS Functional Rating Scale (FRSr), the study population was divided into responders (group I, n = 17) and non-responders (group II, n = 23). A thorough analysis of the pro-inflammatory expression profiles, regulated miRNA pathways, and global gene expression profiles at the RNA level revealed the local and systemic effects of Lin– cell therapy on the immune system of patients with ALS. The autologous application of Lin– cells in CSF modulates immune processes and might prevent the progression of neurodegeneration. However, further in-depth studies are necessary to confirm the findings, and prolonged intervention is needed to maintain therapeutic effects.

1 March 2019 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
KMKarolina Machowska-Sempruch
Karolina Machowska-Sempruch
ACAnna Bajer- Czajkowska
Anna Bajer- Czajkowska
KMKarol Makarewicz
Karol Makarewicz
KZKarolina Zaryczańska
Karolina Zaryczańska
AKAdam Koryzma
Adam Koryzma
PNPrzemysław Nowacki
Przemysław Nowacki

14 December 2020 in Stem Cells International
Verified
Journal Article
Open access
PDF file
ASAnna Sobuś
Anna Sobuś
BBBartłomiej Baumert
Bartłomiej Baumert
WPWioletta Pawlukowska
Wioletta Pawlukowska
MGMONIKA GOŁĄB-JANOWSKA
MONIKA GOŁĄB-JANOWSKA
EPEdyta Paczkowska
Edyta Paczkowska
BMBogusław Machaliński
Bogusław Machaliński
Amyotrophic lateral sclerosis (ALS) remains a fatal, neurodegenerative disease frequently leading to dysarthria and impaired swallowing. Better understanding of ALS pathophysiology is prompting the use of humoral cell therapies. Hence, a repeated cellular therapy was applied to ALS patients as an attempt to prevent speech deterioration. Autologous bone marrow-derived lineage-negative (Lin−) cells were intrathecally administered three times at six-week intervals to 42 sporadic ALS patients. Patients were examined for articulatory functions using subjective (VHI) and objective (FDA) scales. Selected trophic, proinflammatory factors and expression profiles of miRNA were measured in cerebrospinal fluid (CSF) and plasma by multiplex Luminex and q-PCR in different timepoints. Of the 42 patients who received the Lin− cells, 6 showed improvement in articulatory functions, 27 remained stable, and 9 deteriorated after 18 weeks of therapy according to FDA scale. Clinical improvement was particularly evident by the 7th day of each cell application and concerned better cough and swallow reflex, soft palate, laryngeal time, pitch, and volume. These results correlated with significant changes in the concentration of various trophic and proinflammatory factors and miRNA expression profiles. A multiple application of Lin− cells proved to be safe and feasible. The repeated procedure can potentate a humoral effect and prevent speech deterioration. A short-lasting trophic effect of each Lin− cells administration was observed on local and systemic level. However, further in-depth studies are necessary to sustain the beneficial effect.

11 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAnna Sobuś
Anna Sobuś
BBBartłomiej Baumert
Bartłomiej Baumert
MGMONIKA GOŁĄB-JANOWSKA
MONIKA GOŁĄB-JANOWSKA
PKPiotr Kulig
Piotr Kulig
EPEdyta Paczkowska
Edyta Paczkowska
BMBogusław Machaliński
Bogusław Machaliński
ALS remains a fatal, neurodegenerative motor neuron disease. Numerous studies seem to confirm that innate immune system is involved in the pathophysiology of ALS. Hence, the assessment of the complement system and attempts to modify its activity remain the target of medical intervention in ALS. In the present study, three intrathecal administrations of autologous bone marrow-derived lineage-negative (Lin–) cells were performed every 6 weeks in 20 sporadic ALS patients. The concentrations of various complement components in the cerebrospinal fluid and plasma at different time points after cell injection were quantified using a Luminex multiplex. The results of the complement system were correlated with the level of leukocytes, neutrophils, lymphocytes, fibrinogen and CRP in the peripheral blood and the functional status of ALS patients using Norris and ALS-FRSr scales. The study showed a statistically significant decrease in plasma C3b concentration in all 7th days after cell application. In parallel, a peak decrease in neutrophil count and CRP level was observed on days 5–7, with a simultaneous maximum clinical improvement on days 7–28 of each Lin– cell administration. Adjuvant Lin– cell therapy appears to have the silencing potential on the complement-mediated immune system and thus suppress pro-inflammatory reactions responsible for neurodegeneration. However, further in-depth studies are necessary to address this issue.